Please login to the form below

Eliquis

This page shows the latest Eliquis news and features for those working in and with pharma, biotech and healthcare.

Blood thinner Eliquis also performed strongly, with BMS reporting a 29% increase in the quarter to $2.7bn.

Pfizer lifts 2021 guidance as sales of its BioNTech-partnered vaccine continue to climb

Other notable gains in the quarter included rare disease medication Vyndaqel/Vyndamax, which was up by 77%, while sales of its anticoagulant therapy Eliquis were also up by 13% driven by
Pfizer’s COVID-19 vaccine yields $3.5bn in first quarter sales

Elsewhere, Pfizer reported a 25% increase in sales for anticoagulant med Eliquis, led by growth in the US, emerging markets and developed Europe, as well as an 88% operational growth for
UPDATED: BMS completes $13.1bn acquisition of MyoKardia

This includes the company’s oral anticoagulant Eliquis (apixaban), BMS’ second biggest product after cancer immunotherapy Opdivo (nivolumab). ... However, BMS is facing competition from generic rivals of Eliquis – in December 2019, the FDA approved
Bristol-Myers Squibb’s revenues rise on Celgene acquisition

The positive quarterly results build on BMS’ key patent challenge victory on Wednesday for its blood thinner Eliquis (apixaban). ... Eliquis was the second biggest seller in the second quarter, bringing in $4.8bn.
Celgene drugs drive BMS to a buoyant Q4, but Opdivo stalls

BMS’ well-established anticoagulant Eliquis (apixaban) had another strong quarter with a 19% rise to just over $2bn, while multiple myeloma drug Empliciti (elotuzumab) grew by more than a third to

More from news
Approximately 15 fully matching, plus 82 partially matching documents found.

The handover: Pfizer reshapes itself for a new era

Innovative health revenue increased 4% to $8.47bn, lifted by sales of blood thinner Eliquis and breast cancer drug Ibrance outside the US, among others.
The good, the bad and the ugly

This was largely thanks to Eliquis overtaking Bayer’s Xarelto as the leader in novel oral anticoagulants.
Modern anticoagulants threaten status quo

Apixaban. Bristol-Myers Squibb and Pfizer are developing apixaban (Eliquis), which is an oral, twice-daily, selective factor Xa inhibitor.

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

PPD expands global product department with new therapeutic area heads

Puneet Mohan (left) comes to PPD from Bristol-Myers Squibb, where he most recently served as executive director of global clinical development and global clinical leader for Eliquis (apixaban).

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Senior Account Management Trainer, Medical Communications, Londo...: Highly competitive salary

Freelance Scientific Director, Medical Communications, London/ S...: Highly competitive salary

Senior Account Director, Medical & Brand Communications, Lon...: Highly competitive salary

Medical Writers (All levels) Editorial / Scientific Leads & ...: Highly Competitive Remuneration packages

Entry Level Account Executive – Healthcare Advertising – London...: Salary TBC

Home Working Medical Copy Writer & Senior Medical Copy Write...: Highly Competitive Salary, Bonus &Benefits

Account Director, Medical & Brand Communications, London/ SE...: Highly competitive salary

Editorial Director - UK, , EUROPE, REMOTE.: Highly Competitive Salary, Bonus &Benefits

No results were found

Add my company

Graphite is a digital agency which partners with globally respected pharma and healthcare organisations to create powerful digital experiences. We...

Robust Review: COVID19 Assessment: See how our client utilized Rapid Payer Response (RPR) to stay informed and gain continuous insights during the recent global pandemic (COVID19)...
All change – how untangling human behaviour can encourage better health: Driving better patient outcomes through clear, achievable practical steps that are underpinned by transparent evidence...
Health literacy in the time of COVID-19: In a time when much of the media’s focus is on the ongoing COVID-19 pandemic and the differences in vaccination rates between various regions, countries, and socioeconomic groups, improving health...

Email:
Password: